Digital Pharmacoepidemiology of Glucagon-like Peptide-1 Receptor Agonists in Russia: A Retrospective Search Query Analysis (2018–2026)
Pharmacoepidemiology · 23.07.2026 · 5 (3) · 25
DOI: 10.3390/pharma5030025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology, online erschienen am 23.07.2026. Verfasst von Stanislav Kotlyarov und 1 weiteren Autor:innen. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists have revolutionized the treatment of type 2 diabetes and obesity. The rapid growth in public interest, off-label use, and the emergence of counterfeit drugs underscores the need for timely monitoring of information demand.
Objective
The objective of this study is to quantitatively characterize the temporal dynamics, market concentration, seasonality, and semantic structure of Russian-language search queries regarding GLP-1RAs and GLP-1/GIP dual agonists and to assess their correlation with pharmaceutical demand. Materials and Methods: This was a retrospective study of Yandex.Wordstat data from March 2018 to March 2026 (covering 97 months, 27 INNs and brand names). Time series analysis (trends, structural breaks, Seasonal-Trend decomposition based on Loess (STL decomposition)), calculation of the Herfindahl–Hirschman Index (HHI), and semantic analysis of 4562 unique formulations (bigrams, trigrams, Term Frequency–Inverse Document Frequency (TF-IDF), thematic classification, morphological normalization) were performed. Validation was conducted using DSM Group pharmacy sales data.
Results
A total of 46.05 million queries were analyzed. Interest in semaglutide increased 215-fold, with the structural break point identified in January 2021. The HHI decreased from 0.311 (indicating a highly concentrated market) to 0.141 (indicating a competitive market). The share of diabetes-related queries did not exceed 0.46%, while the share of weight-loss-related queries reached 13.91%, and the share of commercial-component queries reached 41.1%. Four semantic signatures were identified: brand-dominant (Ozempic), instruction-targeted (Saxenda), dose-commercial (Tirzetta), and instruction-commercial (Trulicity). No statistically significant seasonality was confirmed after adjustment for multiple comparisons. The correlation between search interest and pharmacy sales was the strongest for Tirzetta (r = 0.976; n = 8; p < 0.001) and remained significant after trend removal (first differences: r = 0.819; p = 0.024).
Conclusions
Yandex.Wordstat data provide a valuable supplementary source for digital pharmacoepidemiology. A systematic discrepancy was found between registered indications and actual information demand, a finding that has significant implications for pharmacovigilance and healthcare planning.
Zitieren
APA
Kotlyarov, S., & Kotlyarova, A. (2026). Digital Pharmacoepidemiology of Glucagon-like Peptide-1 Receptor Agonists in Russia: A Retrospective Search Query Analysis (2018–2026). Pharmacoepidemiology, 5(3), 25. https://doi.org/10.3390/pharma5030025
Vancouver
Kotlyarov S, Kotlyarova A. Digital Pharmacoepidemiology of Glucagon-like Peptide-1 Receptor Agonists in Russia: A Retrospective Search Query Analysis (2018–2026). Pharmacoepidemiology. 2026;5(3):25. doi:10.3390/pharma5030025
BibTeX
@article{Kotlyarov2026,
author = {Kotlyarov, Stanislav and Kotlyarova, Anna},
title = {Digital Pharmacoepidemiology of Glucagon-like Peptide-1 Receptor Agonists in Russia: A Retrospective Search Query Analysis (2018–2026)},
journal = {Pharmacoepidemiology},
year = {2026},
volume = {5},
number = {3},
pages = {25},
doi = {10.3390/pharma5030025}
}
EUVIMED